Table 3.
Association between PFS and Clinicopathological Features of DLBCL Patients
| Characteristics | PFS (Months) | p Value |
|---|---|---|
| Sex | >0.05 | |
| Male | not reached | |
| Female | 25 | |
| Age (years) | >0.05 | |
| <60 | not reached | |
| ≥60 | not reached | |
| Subtype | >0.05 | |
| ABC | 28 | |
| GCB | not reached | |
| B symptoms | >0.05 | |
| Absent | not reached | |
| Present | not reached | |
| LDH | >0.05 | |
| Normal | not reached | |
| Elevated | 24 | |
| Ann Arbor stage | 0.031 | |
| I+II | 23 | |
| III+IV | not reached | |
| IPI score | >0.05 | |
| Low-risk group | not reached | |
| Low- to medium-risk group | not reached | |
| High- to medium-risk group | 23 | |
| High-risk group | 16 |
ABC, activated B cell subtype; DLCBL, diffuse large B cell lymphoma; GCB, germinal center B cell; IPI, international prognostic index; LDH, lactate dehydrogenase; PFS, progression-free survival.